Global Recombinant FSH Injections Market Research Report 2024

Publication ID:

PB502248913

Publication Date:

February 28, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Follicle Stimulating Hormone (FSH) injections are pharmaceutical preparations containing the hormone FSH, a crucial component in the regulation of reproductive processes. FSH is produced by the pituitary gland and plays a key role in the stimulation of ovarian follicles in females and sperm production in males. FSH injections are commonly used in assisted reproductive technologies, such as in vitro fertilization (IVF), to enhance the development and maturation of multiple follicles in the ovaries. In fertility treatments, these injections help regulate and stimulate the ovaries to produce more eggs, increasing the chances of successful fertilization and pregnancy.
Human follicle stimulating hormone (FSH) includes urinary human follicle stimulating hormone (uFSH) and recombinant FSH (rFSH). According to expert consensus, recombinant follicle-stimulating hormone is available in two dosage forms: powder injection and water injection.

The global Recombinant FSH Injections market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The fertility preservation and infertility treatment market has witnessed significant growth in recent years, driven by factors such as increasing infertility rates, delayed pregnancies, advancements in assisted reproductive technologies (ART), and growing awareness. Fertility preservation technologies, including egg freezing and sperm banking, have gained popularity among individuals seeking to preserve their reproductive potential. In the infertility treatment segment, in vitro fertilization (IVF), intrauterine insemination (IUI), and other ART procedures have become mainstream options. Future developments are anticipated in areas such as personalized medicine, gene editing technologies, and improved success rates in ART procedures. The market is likely to see ongoing advancements, innovations, and collaborations aimed at addressing infertility challenges and expanding the range of options available to individuals and couples.

This report aims to provide a comprehensive presentation of the global market for Recombinant FSH Injections, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant FSH Injections.

Report Scope

The Recombinant FSH Injections market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Recombinant FSH Injections market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Recombinant FSH Injections manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

By Company

Gonal-F (Merck)

Follistim (Organon)

Bravelle (Ferring)

Menopur (Ferring)

Fostimon (IBSA)

Puregon (Organon)

BEMFOLA (Gedeon Richter)

Follitrope (LG Chem)

GenSci

Segment by Type

Powder

Liquid

Segment by Application

IVF and Embryo Transfer

Infertility Treatment

Consumption by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Southeast Asia

China Taiwan

Australia

Latin America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Detailed analysis of Recombinant FSH Injections manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Sales, revenue of Recombinant FSH Injections in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Recombinant FSH Injections Market Overview

1.1 Product Overview and Scope of Recombinant FSH Injections

1.2 Recombinant FSH Injections Segment by Type

1.2.1 Global Recombinant FSH Injections Market Value Comparison by Type (2024-2030)

1.2.2 Powder

1.2.3 Liquid

1.3 Recombinant FSH Injections Segment by Application

1.3.1 Global Recombinant FSH Injections Market Value by Application: (2024-2030)

1.3.2 IVF and Embryo Transfer

1.3.3 Infertility Treatment

1.4 Global Recombinant FSH Injections Market Size Estimates and Forecasts

1.4.1 Global Recombinant FSH Injections Revenue 2019-2030

1.4.2 Global Recombinant FSH Injections Sales 2019-2030

1.4.3 Global Recombinant FSH Injections Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Recombinant FSH Injections Market Competition by Manufacturers

2.1 Global Recombinant FSH Injections Sales Market Share by Manufacturers (2019-2024)

2.2 Global Recombinant FSH Injections Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Recombinant FSH Injections Average Price by Manufacturers (2019-2024)

2.4 Global Recombinant FSH Injections Industry Ranking 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Recombinant FSH Injections, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Recombinant FSH Injections, Product Type & Application

2.7 Recombinant FSH Injections Market Competitive Situation and Trends

2.7.1 Recombinant FSH Injections Market Concentration Rate

2.7.2 The Global Top 5 and Top 10 Largest Recombinant FSH Injections Players Market Share by Revenue

2.7.3 Global Recombinant FSH Injections Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Recombinant FSH Injections Retrospective Market Scenario by Region

3.1 Global Recombinant FSH Injections Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Recombinant FSH Injections Global Recombinant FSH Injections Sales by Region: 2019-2030

3.2.1 Global Recombinant FSH Injections Sales by Region: 2019-2024

3.2.2 Global Recombinant FSH Injections Sales by Region: 2025-2030

3.3 Global Recombinant FSH Injections Global Recombinant FSH Injections Revenue by Region: 2019-2030

3.3.1 Global Recombinant FSH Injections Revenue by Region: 2019-2024

3.3.2 Global Recombinant FSH Injections Revenue by Region: 2025-2030

3.4 North America Recombinant FSH Injections Market Facts & Figures by Country

3.4.1 North America Recombinant FSH Injections Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Recombinant FSH Injections Sales by Country (2019-2030)

3.4.3 North America Recombinant FSH Injections Revenue by Country (2019-2030)

3.4.4 United States

3.4.5 Canada

3.5 Europe Recombinant FSH Injections Market Facts & Figures by Country

3.5.1 Europe Recombinant FSH Injections Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Recombinant FSH Injections Sales by Country (2019-2030)

3.5.3 Europe Recombinant FSH Injections Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Netherlands

3.6 Asia Pacific Recombinant FSH Injections Market Facts & Figures by Country

3.6.1 Asia Pacific Recombinant FSH Injections Market Size by Country: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Recombinant FSH Injections Sales by Country (2019-2030)

3.6.3 Asia Pacific Recombinant FSH Injections Revenue by Country (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Southeast Asia

3.6.9 China Taiwan

3.6.10 Australia

3.7 Latin America Recombinant FSH Injections Market Facts & Figures by Country

3.7.1 Latin America Recombinant FSH Injections Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Recombinant FSH Injections Sales by Country (2019-2030)

3.7.3 Latin America Recombinant FSH Injections Revenue by Country (2019-2030)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa Recombinant FSH Injections Market Facts & Figures by Country

3.8.1 Middle East and Africa Recombinant FSH Injections Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Recombinant FSH Injections Sales by Country (2019-2030)

3.8.3 Middle East and Africa Recombinant FSH Injections Revenue by Country (2019-2030)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Recombinant FSH Injections Sales by Type (2019-2030)

4.1.1 Global Recombinant FSH Injections Sales by Type (2019-2024)

4.1.2 Global Recombinant FSH Injections Sales by Type (2025-2030)

4.1.3 Global Recombinant FSH Injections Sales Market Share by Type (2019-2030)

4.2 Global Recombinant FSH Injections Revenue by Type (2019-2030)

4.2.1 Global Recombinant FSH Injections Revenue by Type (2019-2024)

4.2.2 Global Recombinant FSH Injections Revenue by Type (2025-2030)

4.2.3 Global Recombinant FSH Injections Revenue Market Share by Type (2019-2030)

4.3 Global Recombinant FSH Injections Price by Type (2019-2030)

5 Segment by Application

5.1 Global Recombinant FSH Injections Sales by Application (2019-2030)

5.1.1 Global Recombinant FSH Injections Sales by Application (2019-2024)

5.1.2 Global Recombinant FSH Injections Sales by Application (2025-2030)

5.1.3 Global Recombinant FSH Injections Sales Market Share by Application (2019-2030)

5.2 Global Recombinant FSH Injections Revenue by Application (2019-2030)

5.2.1 Global Recombinant FSH Injections Revenue by Application (2019-2024)

5.2.2 Global Recombinant FSH Injections Revenue by Application (2025-2030)

5.2.3 Global Recombinant FSH Injections Revenue Market Share by Application (2019-2030)

5.3 Global Recombinant FSH Injections Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Gonal-F (Merck)

6.1.1 Gonal-F (Merck) Corporation Information

6.1.2 Gonal-F (Merck) Description and Business Overview

6.1.3 Gonal-F (Merck) Recombinant FSH Injections Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Gonal-F (Merck) Recombinant FSH Injections Product Portfolio

6.1.5 Gonal-F (Merck) Recent Developments/Updates

6.2 Follistim (Organon)

6.2.1 Follistim (Organon) Corporation Information

6.2.2 Follistim (Organon) Description and Business Overview

6.2.3 Follistim (Organon) Recombinant FSH Injections Sales, Revenue and Gross Margin (2019-2024)

6.2.4 Follistim (Organon) Recombinant FSH Injections Product Portfolio

6.2.5 Follistim (Organon) Recent Developments/Updates

6.3 Bravelle (Ferring)

6.3.1 Bravelle (Ferring) Corporation Information

6.3.2 Bravelle (Ferring) Description and Business Overview

6.3.3 Bravelle (Ferring) Recombinant FSH Injections Sales, Revenue and Gross Margin (2019-2024)

6.3.4 Bravelle (Ferring) Recombinant FSH Injections Product Portfolio

6.3.5 Bravelle (Ferring) Recent Developments/Updates

6.4 Menopur (Ferring)

6.4.1 Menopur (Ferring) Corporation Information

6.4.2 Menopur (Ferring) Description and Business Overview

6.4.3 Menopur (Ferring) Recombinant FSH Injections Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Menopur (Ferring) Recombinant FSH Injections Product Portfolio

6.4.5 Menopur (Ferring) Recent Developments/Updates

6.5 Fostimon (IBSA)

6.5.1 Fostimon (IBSA) Corporation Information

6.5.2 Fostimon (IBSA) Description and Business Overview

6.5.3 Fostimon (IBSA) Recombinant FSH Injections Sales, Revenue and Gross Margin (2019-2024)

6.5.4 Fostimon (IBSA) Recombinant FSH Injections Product Portfolio

6.5.5 Fostimon (IBSA) Recent Developments/Updates

6.6 Puregon (Organon)

6.6.1 Puregon (Organon) Corporation Information

6.6.2 Puregon (Organon) Description and Business Overview

6.6.3 Puregon (Organon) Recombinant FSH Injections Sales, Revenue and Gross Margin (2019-2024)

6.6.4 Puregon (Organon) Recombinant FSH Injections Product Portfolio

6.6.5 Puregon (Organon) Recent Developments/Updates

6.7 BEMFOLA (Gedeon Richter)

6.6.1 BEMFOLA (Gedeon Richter) Corporation Information

6.6.2 BEMFOLA (Gedeon Richter) Description and Business Overview

6.6.3 BEMFOLA (Gedeon Richter) Recombinant FSH Injections Sales, Revenue and Gross Margin (2019-2024)

6.4.4 BEMFOLA (Gedeon Richter) Recombinant FSH Injections Product Portfolio

6.7.5 BEMFOLA (Gedeon Richter) Recent Developments/Updates

6.8 Follitrope (LG Chem)

6.8.1 Follitrope (LG Chem) Corporation Information

6.8.2 Follitrope (LG Chem) Description and Business Overview

6.8.3 Follitrope (LG Chem) Recombinant FSH Injections Sales, Revenue and Gross Margin (2019-2024)

6.8.4 Follitrope (LG Chem) Recombinant FSH Injections Product Portfolio

6.8.5 Follitrope (LG Chem) Recent Developments/Updates

6.9 GenSci

6.9.1 GenSci Corporation Information

6.9.2 GenSci Description and Business Overview

6.9.3 GenSci Recombinant FSH Injections Sales, Revenue and Gross Margin (2019-2024)

6.9.4 GenSci Recombinant FSH Injections Product Portfolio

6.9.5 GenSci Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Recombinant FSH Injections Industry Chain Analysis

7.2 Recombinant FSH Injections Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Recombinant FSH Injections Production Mode & Process

7.4 Recombinant FSH Injections Sales and Marketing

7.4.1 Recombinant FSH Injections Sales Channels

7.4.2 Recombinant FSH Injections Distributors

7.5 Recombinant FSH Injections Customers

8 Recombinant FSH Injections Market Dynamics

8.1 Recombinant FSH Injections Industry Trends

8.2 Recombinant FSH Injections Market Drivers

8.3 Recombinant FSH Injections Market Challenges

8.4 Recombinant FSH Injections Market Restraints

9 Research Finding and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

Companies Mentioned:

Gonal-F (Merck)

Follistim (Organon)

Bravelle (Ferring)

Menopur (Ferring)

Fostimon (IBSA)

Puregon (Organon)

BEMFOLA (Gedeon Richter)

Follitrope (LG Chem)

GenSci

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂